Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Melisi, Davide
Quinzii, Alberto
Valente, Monica
Di Giacomo, Anna Maria
Amato, Giovanni
Simonetti, Elena
Zecchetto, Camilla
Casallino, Simona
Leta, Luigi
Messineo, Luisa
Mendo, Lucia
Hammett, Tracey
Deken, Marcel
Di Conza, Giusy
Kaur, Paramjit
Lahn, Michael M. F.
Maio, Michele
机构：
[1] Univ Verona, Verona, Italy
[2] Azienda Osped Univ Integrata, Verona, Italy
[3] Azienda Osped Univ Integrata, Invest Canc Therapeut Clin Unit, Verona, Italy
[4] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
[5] Univ Siena, Siena, Italy
[6] Azienda Osped Univ Senese, UOC Immunoterapia Oncol, Siena, Italy
[7] Azienda Osped Univ Integrata, Med Oncol Unit, Verona, Italy
[8] AOUI Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy
[9] Univ Verona, Scuola Specializzaz Oncol Med, Verona, Italy
[10] iOnctura SA, Geneva, Switzerland
[11] iOnctura BV, Amsterdam, Netherlands
[12] iOnctura, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15130
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC)
    Mahalingam, Devalingam
    Saeed, Anwaar
    Powell, Steven Francis
    Alvaro, Marisol Huerta
    Sahai, Vaibhav
    Coveler, Andrew L.
    Davis, Elizabeth J.
    Steeghs, Neeltje
    Mulcahy, Mary Frances
    Raufi, Alexander G.
    Cavalcante, Ludimila
    Cervantes, Andres
    Berlin, Jordan
    Afanasjeva, Janna
    Mikrut, William
    Smith, Sheri Lynn
    Giles, Francis J.
    Carneiro, Benedito A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-na?ve advanced pancreatic ductal adenocarcinoma
    Zhou Zhu
    Hui Tang
    Jinrong Ying
    Yuejuan Cheng
    Xiang Wang
    Yingyi Wang
    Chunmei Bai
    Cancer Biology & Medicine, 2023, 20 (10) : 765 - 778
  • [33] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-na?ve advanced pancreatic ductal adenocarcinoma
    Zhou Zhu
    Hui Tang
    Jinrong Ying
    Yuejuan Cheng
    Xiang Wang
    Yingyi Wang
    Chunmei Bai
    Cancer Biology & Medicine, 2023, (10) : 765 - 778
  • [34] Adverse events in real-world patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX (FFX) or gemcitabine with nab-paclitaxel (GnP) in the first line (1L)
    Dennen, Syvart
    Silver, Michelle
    Cockrum, Paul
    Paluri, Ravi Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
    Zhu, Zhou
    Tang, Hui
    Ying, Jinrong
    Cheng, Yuejuan
    Wang, Xiang
    Wang, Yingyi
    Bai, Chunmei
    CANCER BIOLOGY & MEDICINE, 2023, 20 (10) : 765 - 778
  • [36] A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    De Jesus-Acosta, Ana
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Maitra, Anirban
    Rasheed, Zeshaan
    Zheng, Lei
    Rajeshkumar, N. V.
    Le, Dung T.
    Hoering, Antje
    Bolejack, Vanessa
    Yabuuchi, Shinichi
    Laheru, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [38] Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
    You, Min Su
    Ryu, Ji Kon
    Choi, Young Hoon
    Choi, Jin Ho
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GUT AND LIVER, 2018, 12 (06) : 728 - 735
  • [39] Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
    Jin, Gang
    Guo, Shiwei
    Zhang, Yanqiao
    Ma, Yue
    Guo, Xiaodong
    Zhou, Xiaocui
    Yu, Qin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
12345